On 28 June 2024, the results of a switching study on Fresenius Kabi’s® (MSB11022 adalimumab biosimilar) were published in Current Medical Research and Opinion, following presentation at the 2024 European Congress of Rheumatology (EULAR) earlier in June. The study demonstrated that switching patients with rheumatoid arthritis from AbbVie’s Humira® (adalimumab) to Idacio® produced comparable results in terms of efficacy, safety and immunogenicity.
The first Humira® biosimilar (Amgen’s Amjevita®) was launched in the US on 31 January 2023, with multiple additional biosimilars entering the US market in July 2023. In February 2024, Teva and Alvotech’s Simlandi® was FDA approved as the first interchangeable, high concentration, citrate free adalimumab biosimilar. Simlandi was launched in the US in May 2024.